Please login to the form below

Not currently logged in
Email:
Password:

US label change could boost Tysabri growth

Biogen Idec and Elan's multiple sclerosis drug can now be used with companion diagnostic to screen patients for side effect

Biogen Idec and Elan's multiple sclerosis drug Tysabri (natalizumab) has had its labelling updated to allow the use of a new companion diagnostic, which could lead to a dramatic increase in prescriptions of the drug.

The diagnostic can screen patients for an increased risk of developing a condition called progressive multifocal leukoencephalopathy (PML), which first emerged as a serious side effect with the drug in 2005.

Tysabri was taken off the market briefly after the risk of PML was identified, but reintroduced in 2006 on the grounds that its benefits outweighed the risks in some MS patients, for example those who have not responded to or cannot tolerate other therapies.

The Stratify JCV kit from Quest Diagnostics tests patients for JC virus, an infection which is invariably found in patients who go on to develop PML on Tysabri therapy. The assay was launched in the US in August and in the EU in May 2011.

In Europe, the EMA approved a change to Tysabri's labelling to allow use of the diagnostic the following June.

However, the FDA extended its review period by three months in order to give it more time to evaluate the Risk Evaluation and Mitigation Strategy (REMS) programme linked to the new labelling.

Identifying which patients are JCV-negative will dramatically increase the potential patient population eligible for treatment with the drug, and some analysts have suggested this could lead to a doubling in usage. Elan reported Tysabri revenues approached $400m in the third quarter of 2011.

On the other hand the test could also restrict Tysabri's usage in JC virus-positive patients who might otherwise have received treatment with it, but given the low rate of PML it is expected that any negative pressure on sales would be slight.

23rd January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics